ReNAgade is acquired by RNA rival a year after megaround-backed launch
Two buzzy, well-funded biotech startups are combining in a bid to create a powerhouse at the bleeding edge of genetic medicines. Orna Therapeutics announced Thursday that it would acquire ReNAgade...
View ArticleAstraZeneca makes license and option deal with Nona Biosciences for $19M upfront
AstraZeneca on Thursday inked a license and option deal with the US offshoot of a Chinese-Dutch company, with an eye to creating antibody-based targeted cancer treatments. The UK pharma will pay Nona...
View ArticleClik here to view.
Startup launches with ‘RNA sensor’ technology from Stanford and MIT to better...
Finding a way to deliver genetic medicines to the right parts of the body is one of the most technologically vexing problems in the biotech industry. Many companies grappling with the issue are trying...
View ArticleClik here to view.
Exclusive: Senior primary care startup Gather Health has raised $16M in a new...
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Gather Health, a primary care company headed by a former VillageMD executive, has raised $16.3 million in...
View ArticleAtropos Health raises $33M to arm doctors and pharma companies with evidence
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) With $33 million in fresh funding, Atropos Health — a startup using data from past patients’ cases to...
View ArticleChinese CDMO takes over Pfizer’s UK facility; Serum Institute ships malaria...
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Asymchem Laboratories will take over operations at Pfizer’s API...
View ArticleClik here to view.
SR One raises $200M+ for third fund, still with GSK support
SR One, a life sciences venture capital firm that years ago split from GSK, has raised more than $200 million for a growth opportunities fund, it told Endpoints News. Jake Nunn The fund is a “natural...
View ArticleBicycle’s $555M placement; Tango Therapeutics scraps cancer program
Plus, news about Sanofi, XGEN Ventures, Owkin and Idorsia: Bicycle Therapeutics to raise $555M in one of the biggest PIPEs of the year: The company’s stock $BCYC was up 20% on Thursday morning after it...
View ArticleMerck KGaA avoids prosecution after cooperating with DOJ to uncover China...
Merck KGaA’s subsidiary MilliporeSigma has evaded charges from the US Department of Justice after exposing an alleged eight-year scheme by a former employee and his accomplice to illegally ship...
View ArticleCytokinetics CEO defends Royalty Pharma deal: 'That narrative was hijacked'
Cytokinetics CEO Robert Blum blamed investor frustration over a deal with Royalty Pharma on a “hijacked” narrative that the company would be better off selling itself than continuing on its own. On...
View ArticleClik here to view.
Hornet Therapeutics revives former Kyowa Kirin cancer drug for...
Hornet Therapeutics is on a mission to prevent and treat conditions related to the Epstein-Barr virus (EBV) with the help of a drug candidate shelved by Kyowa Kirin. With $5 million in seed funding...
View ArticleEuropean Commission finalizes joint clinical assessment rules for member...
The European Commission on Thursday finalized rules on how it pools expertise from across the EU to assess the effectiveness of new drugs when compared to drugs already on the market. The rules are...
View ArticleTalc claimants file class action suit accusing J&J of fraud over bankruptcy...
As Johnson & Johnson attempts to settle tens of thousands of talc lawsuits, a group of five plaintiffs filed new litigation on Tuesday accusing the company of efforts to “hinder, delay, and...
View Article#ASCO24 abstracts are out, with results from Nimbus, Nuvation, Pfizer and J&J
Abstracts for the American Society of Clinical Oncology are out, with new data from Pfizer’s ADC, Nimbus Therapeutics’ immuno-oncology drug, Nuvation Bio’s ROS1 inhibitor and new data from J&J in...
View Article#ASCO24: Nuvation Bio shares pivotal China data for cancer drug from AnHeart...
Nuvation Bio showcased longer-term Phase 2 data around the next-gen ROS1 inhibitor it hopes will give Pfizer and Bristol Myers Squibb a run for their money. In a study conducted in China, taletrectinib...
View ArticleClik here to view.
#ASCO24: Pfizer shares the ADC data that convinced it to start a Phase 3 lung...
When Pfizer laid out the ambitious vision for its new oncology division in February, it announced that it was taking the antibody-drug conjugate sigvotatug vedotin directly from Phase 1 to Phase 3. Now...
View Article#ASCO24: Nimbus shares new data, 'grand' hopes for HPK1 cancer drug, after...
Just over a year ago, Nimbus Therapeutics closed one of the biggest single-drug deals in biotech, selling its TYK2 inhibitor to Takeda for $4 billion upfront. Now, CEO Jeb Keiper is planning the...
View Article#ASCO24: Merck, Kelun trumpet Phase 3 breast cancer data for anti-TROP2 ADC
Merck and Kelun-Biotech revealed Phase 3 breast cancer data for the lead antibody-drug conjugate in their potentially $12 billion partnership. In a Phase 3 trial for locally recurrent or metastatic...
View ArticleClik here to view.
#ASCO24: J&J plans for capped, flexible dosing after four patient deaths in...
An experimental prostate cancer drug developed by Johnson & Johnson that uses a rare radioactive particle called actinium-225 led to three patients seeing their tumors shrink substantially, but...
View ArticleClik here to view.
Idorsia’s Jean-Paul Clozel retires as CEO, plots next steps; CRISPR...
Jean-Paul Clozel → Jean-Paul Clozel is ready to pass the torch at his Actelion follow-up Idorsia, but he doesn’t want to walk away from the company altogether. Clozel will retire as CEO on June 13, and...
View Article